Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02312193

Enrollment

Registered

2014-12-09

Start date

2015-01-31

Completion date

2020-12-31

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

hypertension, myogenic tone

Brief summary

Aim of this study is to enhance the knowledge of myogenic tone alterations in hypertensive patients and to better understand the mechanisms controlling the myogenic tone. Evaluations will be performed through ex vivo studies of peripheral arterioles in human adipose tissue from lumbar muscle, isolated from biopsies. This will allow investigators to evaluate the myogenic function in response to progressive blood pressure increases, in order to correlate myogenic function to arterial hypertension and to the molecular mechanisms already identified in the preclinical models.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Males or females between 30 and 70 years of age * Hypertensive patients: Patients with a previous diagnosis of hypertension * Normotensive patients: subjects without story of hypertension * Written informed consent

Exclusion criteria

* Severe hypertension (eg, systolic \>180 mm Hg, diastolic \>110 mm Hg) * Manifested or suspected secondary hypertension (coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, pheochromocytoma) * History of cardiac complications (previous acute myocardial infarction (AMI), unstabile angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), congestive heart failure (NYHA II-IV)) * Diabetes mellitus * Renal pathologies (creatinine clearance \< 30 ml/min) * Severe hepatic dysfunction

Design outcomes

Primary

Measure	Time frame
Myogenic tone measured by micromyographic technique to evaluate small-artery morphology.	12 months

Countries

Italy

Outcome results